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AbstrAct
Introduction Stroke is a leading cause of adult disability 
and death worldwide. The neurological impairments 
associated with stroke prevent patients from performing 
basic daily activities and have enormous impact on 
families and caregivers. Practical and accurate tools to 
assist in predicting outcome after stroke at patient level 
can provide significant aid for patient management. 
Furthermore, prediction models of this kind can be useful 
for clinical research, health economics, policymaking and 
clinical decision support.
Methods 2869 patients with first-ever stroke from 
South London Stroke Register (SLSR) (1995–2004) will 
be included in the development cohort. We will use 
information captured after baseline to construct multilevel 
models and a Cox proportional hazard model to predict 
cognitive impairment, functional outcome and mortality 
up to 5 years after stroke. Repeated random subsampling 
validation (Monte Carlo cross-validation) will be evaluated 
in model development. Data from participants recruited to 
the stroke register (2005–2014) will be used for temporal 
validation of the models. Data from participants recruited 
to the Dijon Stroke Register (1985–2015) will be used for 
external validation. Discrimination, calibration and clinical 
utility of the models will be presented.
Ethics Patients, or for patients who cannot consent their 
relatives, gave written informed consent to participate in 
stroke-related studies within the SLSR. The SLSR design 
was approved by the ethics committees of Guy’s and St 
Thomas’ NHS Foundation Trust, Kings College Hospital, 
Queens Square and Westminster Hospitals (London). The 
Dijon Stroke Registry was approved by the Comité National 
des Registres and the InVS and has authorisation of the 
Commission Nationale de l’Informatique et des Libertés.
IntroductIon
Stroke is one of the most common causes of 
serious adult physical disability and the third 
most common cause of death worldwide.1 
Despite the introduction of effective treat-
ments for acute stroke, early rehabilitation and 
secondary prevention, the majority of stroke 
survivors have medical comorbidities, physical 
and/or cognitive impairments that require 
ongoing active assessment and management.2 
Stroke can be seen as a chronic condition, span-
ning not only the incident event and formal 
rehabilitation but the rest of the patient’s life. 
Rehabilitation from stroke requires a sustained, 
coordinated effort from informed multidis-
ciplinary teams (MDTs), as well as patients 
and carers, both in the clinical setting and in 
the community.3 MDTs and patients make 
numerous decisions on the basis of an estimated 
probability that a specific event will occur in the 
future. These predictions are used for planning 
lifestyle or therapeutic decisions on the basis 
of the risk of developing a particular outcome 
or state of health.4–6 More recently such esti-
mates are used to risk-stratify participants in 
therapeutic intervention trials and case-mix 
classifications.7 8
Information from a single predictor is often 
insufficient to provide reliable estimates of 
prognostic probabilities or risks, particularly 
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Protocol
strengths and limitations of this study
 ► First prognostic tool in stroke to follow, a priori, 
the Prognosis Research Strategy  (PROGRESS) 
framework, and Transparent Reporting of a 
multivariable prediction model for Individual 
Prognosis Or Diagnosis (TRIPOD) reporting 
guidelines for prognostic research.
 ► Specifies statistical analysis plan and informative 
levels of tool performance to increase transparency 
of results and the final report.
 ► The proposed study predicts outcomes longitudinally, 
which may be more reflective of clinical needs than 
predictions made at predefined time points.
 ► The proposed study is restricted by the use of 
predictor variables measured in previous data sets 
and the limitations of these measures. The external 
validation is not independent.
group.bmj.com on September 5, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Fahey M, et al. BMJ Open 2017;7:e014607. doi:10.1136/bmjopen-2016-014607
Open Access 
in complex patients, for example those with comorbid-
ities.9 10 Therefore probability estimates are commonly 
based on combining information from multiple predic-
tors to form a multivariable clinical prediction model 
(CPM).11 12
CPMs are abundant in prognostic research literature, 
but few are implemented or used in routine clinical prac-
tice.13 One explanation for this is that, although many 
models have been developed,14 15 they have limited utility 
for clinical applications, particularly in a long-term care 
setting. Progression or regression of disease is highly vari-
able both over time and between individuals.16 Current 
CPMs typically estimate risk at predefined time points. 
With variability in mind, time series data and methods may 
be more appropriate for accurately capturing recovery, 
particularly when the aim is planning immediate and 
long-term care simultaneously for individual patients.
There is generally a lack of confidence among clinicians 
in applying risk scores in practice. Many believe there is 
the lack of sufficient evidence to demonstrate the repro-
ducibility and transportability of the model in a different 
population.17 To be considered useful, a risk score should 
be clinically credible, accurate (well calibrated with good 
discriminative ability) and have generality (be externally 
validated).17
We have evaluated the accuracy of existing models 
in predicting stroke outcomes by systematic review 
of literature and meta-analysis. The systematic review 
and meta-analysis concluded that existing models have 
much potential and advised to build on previous work, 
as opposed to designing new models, in developing CPMs 
suitable for the long-term care setting.15 Models predicting 
outcomes longitudinally, as opposed to predefined time 
points, may best support patient management and so we 
will build on work by colleagues in this area.18 19
objEctIvEs
Primary objectives
The primary objectives were to develop and internally vali-
date prediction models in patients with ischaemic stroke 
for functional outcome, survival and cognitive impair-
ment at 5 years, and to externally validate and update 
these models through an external data set of patients with 
ischaemic stroke.
secondary objectives
The secondary objectives were to assess deviations of 
predicted recovery curves, to investigate why patients 
with stroke regain different recovery that plateaued at 
different levels, and to derive and validate scoring system 
for classifying risks (case-mix classification) from these 
patient-centred predictive models.
MEthods
This cohort study is informed by the Prognosis Research 
Strategy (PROGRESS) framework and recommendations 
by authors in the field. We will report the study protocol 
using the Transparent Reporting of a multivariable 
prediction model for Individual Prognosis Or Diagnosis 
(TRIPOD) statement for prediction studies.20
source of data
The study is a prospective longitudinal cohort study. The 
data source is the South London Stroke Register (SLSR), an 
ongoing, prospective, population-based stroke register set 
up in January 1995 recording all first-ever strokes in patients 
of all ages for an inner area of South London. The methods 
of the SLSR have been described previously in detail2 and 
are summarised here. Stroke was defined according to the 
WHO criteria and Oxfordshire Community Stroke Project 
Classification. Multiple overlapping sources of informa-
tion are employed. Data from 1995 to 2016 will be used for 
model derivation and internal validation.
Participants
Patients admitted to hospitals serving the study area (two 
teaching hospitals within and three hospitals outside 
the study area) are identified by regular reviews of acute 
wards admitting patients with stroke, and national data 
on patients admitted to any hospital in England and 
Wales with a diagnosis of stroke are screened for addi-
tional patients. All general practitioners (n=699 (2011)) 
within and on the borders of the study area are contacted 
regularly and asked to notify the SLSR of patients with 
stroke. Referral of non-hospitalised patients with stroke 
to a neurovascular outpatient clinic (from 2003) or domi-
ciliary visit to patients by the study team is also available to 
general practitioners. Community therapists are contacted 
every 3 months. Death certificates are checked regularly. 
Patients are assessed at the stroke onset, 3 months and 
annually after stroke. Participants receive treatments in 
line with the UK national clinical guidelines for stroke. 
Completeness of case ascertainment has been estimated 
at 88% by a multinomial logit capture–recapture model 
using the methods described in detail elsewhere.21
outcome
The outcomes of interest are mortality measured as time 
to event, functional outcome measured using the Barthel 
Index (BI) and cognitive impairment measured using the 
Mini-Mental State Exam (MMSE) or Abbreviated Mental 
Test (AMT), measured at baseline, 3 months and annually 
up to 5 years after stroke. Specially trained nurses and field 
workers collect all data prospectively whenever feasible. A 
study doctor verifies the diagnosis of stroke. Patients are 
examined within 48 hours of referral to the SLSR where 
possible. Follow-up data are collected by validated postal 
or face-to-face instruments with patients and/or their 
carers. Outcome definition and measurement method 
are the same for all patients. Data collection is carried out 
by a third party, uninvolved in this study.
Predictors
Candidate predictors to be considered in the predic-
tion models will be based on predictor variables 
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as identified in previous systematic reviews in this 
field,15 22 ease and reliability of measurement in clinical 
setting and theoretical association with the progres-
sion of outcomes. The number of variables required 
to ensure adequate power based on our target sample 
size (see below), to avoid overfitting and to encourage 
parsimony and applicability of the model in clinical 
practice will also be considered. Number, type, defi-
nition, method for measurement and handling of 
candidate predictors in the modelling are listed in 
the data supplement. All predictors are measured 
on patient presentation. Data collection is carried out 
by a third party, not involved in this research.
sample size
Cumulative survival up to 10 years after stroke is esti-
mated at 63.7%, 42.8% and 24.0%, surviving up to 1, 
5 and 10 years, respectively.2 Disability is estimated on 
average at 11% (10-year average and standardised to 
European population in the SLSR).2 Current SLSR 
data (1995–2015) estimate disability (BI >15) at 24.6%, 
23.7% and 26.3% at 1, 5 and 10 years, respectively. 
Cognitive impairment (MMSE <24) is estimated at 
approximately 22% in the first 5 years following stroke 
(age-standardised to European population).23 Current 
SLSR data (1995–2015) estimate cognitive impairment 
at 29.8%, 28.9%, 28.6% at 1, 5 and 10 years, respec-
tively. Rules of thumb for fitting multivariate models 
suggest that 10 events for every variable (EPV) are 
required to avoid overfitting in model development 
studies. Although we are within these limitations, the 
use of this rule can result in small sample sizes, which 
may lead to overfitting and optimism. It is recom-
mended that EPV should be data-driven.24 Sample 
size calculations described by Jinks25 will be used for 
survival analysis. Simulation will be used to determine 
appropriate sample size for prediction models for 
functional outcome and cognitive impairment.
Missing data
Missing data are inevitable in studies with long follow-up 
and may lead to bias and imprecision. Multiple imputa-
tion will be used to impute missing values, under a missing 
at random assumption, so as to reduce bias and avoid 
excluding participants from the analysis.26–30 Imputations 
typically break down when missing data are excessive; 
therefore, data with more than 80% missing data will be 
excluded.
statistical analysis methods
We will develop three CPMs for the outcomes: (1) 
mortality, (2) functional outcome and (3) cognitive 
impairment up to 5 years after stroke. The start point 
is time of stroke and end point is 5 years post stroke.
For predictor selection during multivariate modelling, 
a variable selection and shrinkage procedure will be used 
to decide which of the identified candidate predictor 
variables should be included in the final prediction 
model. Continuous variables will be kept as continuous 
(rather than say dichotomising) to avoid loss of power. 
Non-linear trends will be considered using fractional 
polynomials and the multivariable fractional polynomial 
procedure. Clinically meaningful interactions (eg, time) 
will be included in the model.
We will assess internal validity with a bootstrapping 
procedure for a realistic estimate of the performance 
of prediction models in similar future patients.5 12 The 
bootstrap validation approach uses all of the data to 
develop the prediction model and provides a mecha-
nism to account for model overfitting or uncertainty in 
the entire model development process, thereby quan-
tifying any optimism in the final prediction model. 
Also, it provides for estimating a shrinkage factor that 
can be used to adjust the regression coefficients and 
apparent performance for optimism, such that better 
performance will be obtained in subsequent model 
validation studies and applications.31
External validity will be assessed using data form the 
Dijon Stroke Register (DSR). Patients will be classi-
fied using the estimates of the previously developed 
models and performance assessed. Subgroup analyses 
will be carried out to assess deviations from predicted 
recovery trajectories and investigate why patients with 
stroke regain different recovery that plateaued at 
different levels.
risk groups
Although risk groups (eg, ‘high risk’, ‘moderate risk’, 
‘low risk’) may make models more accessible, no risk 
groups will be created. There is no clear consensus on 
how to create risk groups or how many groups to use.31 
There are concerns that use of risk groups may not be in 
the best interest of patients and may become standard, 
although lacking any rational.31 Also, the simplification 
of predicted probabilities assumes risk is the same for all 
individuals within that category.
development versus validation
Data from the DSR will be used for external validation; its 
methods have been described previously in detail32–34 and 
both data sets are contrasted here. The DSR and SLSR are 
population-based registers; multiple overlapping sources 
of notification are used and stroke is defined according 
to WHO criteria for both. Specially trained field workers 
collect all data. This includes sociodemographic factors, 
disease characteristics, patient history and cardiovas-
cular risk factors in both registers. DSR participants 
are followed up at time of stroke and yearly thereafter; 
these questionnaires are administered in outpatient 
clinics or conducted telephonically by clinical nurses. 
Follow-up procedures in SLSR are similar, but partici-
pants are followed up at 3 months also. In both registers, 
survival is measured using national data, cognitive status 
is measured using either the AMT or the MMSE, and 
disability is measured using BI.
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The flow of participants through the study, including the 
number of participants with and without the outcome, 
and a summary of the follow-up time will be described. 
The characteristics of the participants, including the 
number of participants with missing data for predic-
tors and outcome for both development and validation 
cohorts, will be provided.
Model development
The number of participants and outcome events in each 
analysis will be presented, as well as the unadjusted asso-
ciation between each candidate predictor and outcome.
Model specification
The full prediction model for each outcome will be 
presented, including all regression coefficients, and 
model intercept and baseline survival. Once a final model 
is identified, methods will be applied to simplify and 
adapt the presentation of the model to a scoring system 
to facilitate its application in practice at a later date. An 
explanation of how to use the model and scoring system 
will also be presented.
Model performance
Model performance assessment has been designed using 
the framework described by Steyerberg and colleagues.35 
Model performance will be assessed in derivation and 
validation data sets. For model development studies, we 
are primarily interested in discrimination, because the 
model will be well calibrated (on average) by definition 
when smoothing methods are used. In validation studies, 
assessment of both discrimination and calibration is 
fundamental.35 36 Calibration of the derived models will be 
measured using calibration plot and Hosmer-Lemeshow 
test or counterpart test for the survival model.37 38 Further-
more, they convey no indication of magnitude or direction 
of any miscalibration; hence, calibration plots will also be 
presented. Calibration plots will also be evaluated in rela-
tion to key predictors/subgroups. Discrimination of the 
derived models will be measured using the concordance 
statistic and CIs (c-statistic). The c-index is identical to the 
area under the receiver operating characteristic curve for 
models with binary end points and can be generalised for 
time-to-event (survival) models accounting for censoring. 
A benchmark level of discrimination was determined in 
our meta-analysis for mortality and functional outcome. 
On the basis of the reference standard values in statis-
tics literature39 and those of previous work in stroke, we 
will consider area under the curve values of greater than 
0.8 to be acceptable for these outcomes. Classification 
measures (eg, sensitivity, specificity, predictive values, net 
reclassification improvement) will be presented and cut 
points selected a priori. Decision curve analysis will be 
undertaken to assess clinical utility.40
Model updating
We will update the model if it shows poor performance in 
external data (DSR) by recalibration or revision methods 
depending on discrimination performance (c-statis-
tics <0.80). If model is updated, updating approaches 
recommended by Steyerberg et al13 (model recalibration, 
model revision, model extension) will be adopted as 
appropriate.
conclusIon
We have described the methods and statistical analysis 
plan to develop and to validate a family of CPMs for stroke 
over the long term. To our knowledge, this tool will be the 
first of its kind in stroke to follow, a priori, the PROG-
RESS framework and TRIPOD reporting guidelines for 
prognostic research. Importantly for secondary preven-
tion, the tool will be developed specifically to predict the 
progression of disease and to identify those at high risk of 
an adverse outcome. Results coming from this study will 
be interpreted for both clinical and research purposes.
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